1. WHO Classification of Skin Tumours, 4th edn; 2018.

2. Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T: Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol 2017, 177(2): 359 - 372.

3. Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988, 124(6): 869 - 871.

4. Rosso S, Zanetti R, Martinez C, Tormo MJ, Schraub S, Sancho-Garnier H, Franceschi S, Gafa L, Perea E, Navarro C et al: The multicentre south European study "Helios". II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996, 73(11): 1447 - 1454.

5. Gupta AK, Cardella CJ, Haberman HF: Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986, 122(11): 1288 - 1293.

6. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S: Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999, 40(2 Pt 1): 177 - 186.

7. Patel RV, Clark LN, Lebwohl M, Weinberg JM: Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009, 60(6): 1001 - 1017.

8. Silverberg MJ, Leyden W, Warton EM, Quesenberry CP, Jr., Engels EA, Asgari MM: HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013, 105(5): 350 - 360.

9. Asgari MM, Arron ST, Warton EM, Quesenberry CP, Jr., Weisshaar D: Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs). J Am Acad Dermatol 2015, 73(3): 444 - 450.

10. Brewer JD, Shanafelt TD, Khezri F, Sosa Seda IM, Zubair AS, Baum CL, Arpey CJ, Cerhan JR, Call TG, Roenigk RK et al: Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota. J Am Acad Dermatol 2015, 72(2): 302 - 309.

11. Gerber SR, Seifert B, Inci I, Serra AL, Kohler M, Benden C, Hofbauer GF, Schuurmans MM: Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. J Eur Acad Dermatol Venereol 2015, 29(12): 2451 - 2457.

12. Hock BD, McIntosh ND, McKenzie JL, Pearson JF, Simcock JW, MacPherson SA: Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients. Intern Med J 2016, 46(12): 1414 - 1421.

13. van den Heuvel TR, Wintjens DS, Jeuring SF, Wassink MH, Romberg-Camps MJ, Oostenbrug LE, Sanduleanu S, Hameeteman WH, Zeegers MP, Masclee AA et al: Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer 2016, 139(6): 1270 - 1280.

14. Diffey BL, Norval M, Albers PN, Wright CY: The influence of HIV infection on the age dependence of squamous cell carcinoma of the skin in South Africa. S Afr Med J 2017, 107(2): 127 - 129.

15. Zilinska Z, Sersenova M, Chrastina M, Breza J, Sr., Bena L, Baltesova T, Jurcina A, Roland R, Lackova E, Cellar M et al: Occurrence of malignancies after kidney transplantation in adults: Slovak multicenter experience. Neoplasma 2017, 64(2): 311 - 317.

16. Stern RS, Lunder EJ: Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998, 134(12): 1582 - 1585.

17. Leffell DJ, Carucci JA: Management of Skin Cancer. In: Cancer: Principles and Practice of Oncology. 6th edn. Edited by Devita VT, Hellman S, Rosenberg SA: Lippincott Williams & Wilkins;.

18. Edwards MJ, Hirsch RM, Broadwater JR, Netscher DT, Ames FC: Squamous cell carcinoma arising in previously burned or irradiated skin. Arch Surg 1989, 124(1): 115 - 117.

19. Rowe DE, Carroll RJ, Day CL, Jr.: Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992, 26(6): 976 - 990.

20. Eroglu A, Berberoglu U, Berreroglu S: Risk factors related to locoregional recurrence in squamous cell carcinoma of the skin. J Surg Oncol 1996, 61(2): 124 - 130.

21. Snyder RJ, Stillman RM, Weiss SD: Epidermoid cancers that masquerade as venous ulcer disease. Ostomy Wound Manage 2003, 49(4): 63 - 64, 65 - 66.

22. Combemale P, Bousquet M, Kanitakis J, Bernard P, Angiodermatology Group FSoD: Malignant transformation of leg ulcers: a retrospective study of 85 cases. J Eur Acad Dermatol Venereol 2007, 21(7): 935 - 941.

23. Al-Zacko SM: Malignancy in chronic burn scar: a 20 year experience in Mosul-Iraq. Burns 2013, 39(7): 1488 - 1491.

24. Karasoy Yesilada A, Zeynep Sevim K, Ozgur Sucu D, Akcal A, Karsidag S, Kilinc L, Orhan Kizilkaya H: Marjolin ulcer: clinical experience with 34 patients over 15 years. J Cutan Med Surg 2013, 17(6): 404 - 409.

25. Natafji N, Tidman MJ: Improving detection of non-melanoma skin cancer Non-melanoma skin cancer. Practitioner 2015, 259(1784): 23 - 27, 23.

26. Onesti MG, Fino P, Fioramonti P, Amorosi V, Scuderi N: Ten years of experience in chronic ulcers and malignant transformation. Int Wound J 2015, 12(4): 447 - 450.

27. Khullar G, Saikia UN, De D, Handa S, Das Radotra B: Predisposing factors and histopathological variants of cutaneous squamous cell carcinoma: Experience from a North Indian teaching hospital. Indian J Dermatol Venereol Leprol 2016, 82(3): 273 - 278.

28. Marks R, Rennie G, Selwood TS: Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988, 1(8589): 795 - 797.

29. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial G: Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009, 115(11): 2523 - 2530.

30. Eimpunth S, Goldenberg A, Hamman MS, Oganesyan G, Lee RA, Hunnangkul S, Song SS, Greywal T, Jiang SIB: Squamous Cell Carcinoma In Situ Upstaged to Invasive Squamous Cell Carcinoma: A 5-Year, Single Institution Retrospective Review. Dermatol Surg 2017, 43(5): 698 - 703.

31. Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS: Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014, 134(1): 213 - 220.

32. Luande J, Henschke CI, Mohammed N: The Tanzanian human albino skin. Natural history. Cancer 1985, 55(8): 1823 - 1828.

33. Kraemer KH, Lee MM, Scotto J: Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987, 123(2): 241 - 250.

34. Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, Oh KS, Imoto K, Inui H, Moriwaki S et al: Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011, 48(3): 168 - 176.

35. Mabula JB, Chalya PL, McHembe MD, Jaka H, Giiti G, Rambau P, Masalu N, Kamugisha E, Robert S, Gilyoma JM: Skin cancers among Albinos at a University teaching hospital in Northwestern Tanzania: a retrospective review of 64 cases. BMC Dermatol 2012, 12:5.

36. Halkud R, Shenoy AM, Naik SM, Chavan P, Sidappa KT, Biswas S: Xeroderma pigmentosum: clinicopathological review of the multiple oculocutaneous malignancies and complications. Indian J Surg Oncol 2014, 5(2): 120 - 124.

37. Gandini S, Palli D, Spadola G, Bendinelli B, Cocorocchio E, Stanganelli I, Miligi L, Masala G, Caini S: Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol 2018, 122: 1 - 9.

38. Chen P, Chen F, Zhou B: Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma. Clin Exp Dermatol 2019, 44(3): 243 - 251.

39. Tang H, Fu S, Zhai S, Song Y, Asgari MM, Han J: Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2018, 27(3): 279 - 288.

40. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, Coldiron BM: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010, 146(3): 283 - 287.

41. Lomas A, Leonardi-Bee J, Bath-Hextall F: A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012, 166(5): 1069 - 1080.

42. Rubin AI, Chen EH, Ratner D: Basal-cell carcinoma. N Engl J Med 2005, 353(21): 2262 - 2269.

43. Kuo KY, Batra P, Cho HG, Li S, Chahal HS, Rieger KE, Tang JY, Sarin KY: Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution. J Am Acad Dermatol 2017, 77(2): 233 - 234 e232.

44. Каприн А.Д., Старинский В.В., Петрова Г.В. (eds.): Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2018.

45. Каприн А.Д., Старинский В.В., Петрова Г.В. (eds.): Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2019.

46. International Statistical Classification of Diseases and Related Health Problems 10th Revision [http://apps.who.int/classifications/icd10/browse/2016/en]

47. Brierley JD, Gospodarowicz MK, Wittekind C (eds.): TNM classification of malignant tumors, 8th edn. Oxford, UK: John Wiley & Sons, Inc; 2017.

48. Shmults CD, Blitzblau R, Aasi SA, Alam M, Andersen JS, Bordeaux J, Bowen GM, Carson W, Chen P-L, Contreras CM et al: NCCN Guidelienes Version 1.2020. Squamous Cell Skin Cancer. In.: NCCN; 2019.

49. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL: Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA Dermatol 2016, 152(4): 419 - 428.

50. Swanson NA: Mohs surgery. Technique, indications, applications, and the future. Arch Dermatol 1983, 119(9): 761 - 773.

51. Prieto-Granada C, Rodriguez-Waitkus P: Cutaneous squamous cell carcinoma and related entities: Epidemiology, clinical and histological features, and basic science overview. Curr Probl Cancer 2015, 39(4): 206 - 215.

52. Burton KA, Ashack KA, Khachemoune A: Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol 2016, 17(5): 491 - 508.

53. Kwiek B, Schwartz RA: Keratoacanthoma (KA): An update and review. J Am Acad Dermatol 2016, 74(6): 1220 - 1233.

54. Oshyvalova OO, Kaliuzhna LD, Kropelnytskyi VO: Clinical forms of actinic keratosis and levels of dysplasia of the epidermis. Wiad Lek 2017, 70(6 pt 1): 1072 - 1078.

55. Parekh V, Seykora JT: Cutaneous Squamous Cell Carcinoma. Clin Lab Med 2017, 37(3): 503 - 525.

56. Que SKT, Zwald FO, Schmults CD: Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 2018, 78(2): 237 - 247.

57. deShazo R, Soltani-Arabshahi R, Krishnasamy S, Langley RG, Kalia S, Stahle M, Langholff W, Goyal K, Fakharzadeh S, Galindo C et al: Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2019, 18(10): 1059 - 1060.

58. Elnahas S, Olson MT, Kang P, Panchanathan R, Masuda T, Walia R, Zeitouni NC, Smith MA, Bremner RM: Factors associated with skin cancer in lung transplant recipients: A single-center experience. Clin Transplant 2019: e13718.

59. Huang JT, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Al-Sayegh H, London WB, Marghoob A et al: Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. J Pediatr 2019, 211: 152 - 158.

60. Oliveira WRP, Tirico M, Souza AAV, Codarin FR, Silva LLC, Festa Neto C: Skin lesions in organ transplant recipients: a study of 177 consecutive Brazilian patients. Int J Dermatol 2019, 58(4): 440 - 448.

61. Oh CC, Lee HY, Tan BK, Assam PN, Kee TYS, Pang SM: Dermatological conditions seen in renal transplant recipients in a Singapore tertiary hospital. Singapore Med J 2018, 59(10): 519 - 523.

62. Collins L, Quinn A, Stasko T: Skin Cancer and Immunosuppression. Dermatol Clin 2019, 37(1): 83 - 94.

63. Lee CT, Lehrer EJ, Aphale A, Lango M, Galloway TJ, Zaorsky NG: Surgical excision, Mohs micrographic surgery, external-beam radiotherapy, or brachytherapy for indolent skin cancer: An international meta-analysis of 58 studies with 21,000 patients. Cancer 2019, 125(20): 3582 - 3594.

64. Dinnes J, Deeks JJ, Chuchu N, Matin RN, Wong KY, Aldridge RB, Durack A, Gulati A, Chan SA, Johnston L et al: Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev 2018, 12: CD011901.

65. Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, Wong KY, Aldridge RB, Abbott R et al: Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database of Systematic Reviews 2018(12).

66. Grange F: [Multiple primary melanoma and familial melanoma. Risk evaluation and screening tests. How to evaluate the risk of developing a second melanoma? In what family? Should screening methods be implemented? Which ones and why?]. Ann Dermatol Venereol 1995, 122(5): 365 - 371.

67. Claeson M, Holmstrom P, Hallberg S, Gillstedt M, Gonzalez H, Wennberg AM, Paoli J: Multiple Primary Melanomas: A Common Occurrence in Western Sweden. Acta Derm Venereol 2016.

68. Moore MM, Geller AC, Warton EM, Schwalbe J, Asgari MM: Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. J Am Acad Dermatol 2015, 73(4): 630 - 636.

69. Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Ebell M, Epling JW, Jr., Garcia FA, Gillman MW, Kemper AR et al: Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016, 316(4): 429 - 435.

70. Lallas A, Argenziano G, Zendri E, Moscarella E, Longo C, Grenzi L, Pellacani G, Zalaudek I: Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther 2013, 13(5): 541 - 558.

71. Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR: Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016, 316(4): 436 - 447.

72. Lallas A, Pyne J, Kyrgidis A, Andreani S, Argenziano G, Cavaller A, Giacomel J, Longo C, Malvestiti A, Moscarella E et al: The clinical and dermoscopic features of invasive cutaneous squamous cell carcinoma depend on the histopathological grade of differentiation. Br J Dermatol 2015, 172(5): 1308 - 1315.

73. Manfredini M, Longo C, Ferrari B, Piana S, Benati E, Casari A, Pellacani G, Moscarella E: Dermoscopic and reflectance confocal microscopy features of cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol 2017, 31(11): 1828 - 1833.

74. Weber P, Tschandl P, Sinz C, Kittler H: Dermatoscopy of Neoplastic Skin Lesions: Recent Advances, Updates, and Revisions. Curr Treat Options Oncol 2018, 19(11): 56.

75. Payapvipapong K, Tanaka M: Dermoscopic classification of Bowen"s disease. Australas J Dermatol 2015, 56(1): 32 - 35.

76. Ferrante di Ruffano L, Dinnes J, Chuchu N, Bayliss SE, Takwoingi Y, Davenport C, Matin RN, O"Sullivan C, Roskell D, Deeks JJ et al: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. Cochrane Database Syst Rev 2018, 12: CD013187.

77. Бровкина А.Ф.: Офтальмоонкология. Москва: Медицина; 2002.

78. Бровкина А.Ф., Панова И.Е., Саакян С.В.: Офтальмоонкология: новое за последние два десятилетия. Вестник офтальмологии 2014, 130(6): 13 - 19.

79. Вальский В.В., Бородин Ю.И., Саакян С.В.: Эффективность протонотерапии эпителиальных злокачественных опухолей придаточного аппарата глаза редуцированной суммарной очаговой дозой. Опухоли головы и шеи 2016, 1(6): 47 - 48.

80. Важенина ДА, Васильев СА, Дудник СН: Рецидивирующий базальноклеточный рак кожи век (особенности клинического течения, лечения). Российский медицинский журнал 2016, 11: 36 - 43.

81. Енгибарян МА, Пустовая ИВ, Ульянова ЮВ: Первичная аутопластика в хирургическом лечении опухолей внутреннего угла глаза. Известия ВУЗ Северо-Кавказский Регион Естественные Науки 2011: 34 - 36.

82. Панова ИЕ, Васильев СА, Семенов ЛЕ: Рецидивирующий базальноклеточный рак кожи век. Клиническая офтальмология 2006, 7(1): 11 - 14.

83. Walsh MF, Chang VY, Kohlmann WK, Scott HS, Cunniff C, Bourdeaut F, Molenaar JJ, Porter CC, Sandlund JT, Plon SE et al: Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. Clin Cancer Res 2017, 23(11): e23 - e31.

84. Tofuku Y, Nobeyama Y, Kamide R, Moriwaki S, Nakagawa H: Xeroderma pigmentosum complementation group F: Report of a case and review of Japanese patients. J Dermatol 2015, 42(9): 897 - 899.

85. Pace P: [Eugenic consultation]. Minerva Med 1974, 65(90): 4754 - 4760.

86. Kraemer KH, DiGiovanna JJ: Xeroderma Pigmentosum. In: GeneReviews((R)). edn. Edited by Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A. Seattle (WA); 1993.

87. Naik SM, Shenoy AM, Nanjundappa A, Halkud R, Chavan P, Sidappa K, Gupta S: Cutaneous malignancies in xeroderma pigmentosum: earlier management improves survival. Indian J Otolaryngol Head Neck Surg 2013, 65(2): 162 - 167.

88. Christen-Zaech S, Imoto K, Khan SG, Oh KS, Tamura D, Digiovanna JJ, Boyle J, Patronas NJ, Schiffmann R, Kraemer KH et al: Unexpected occurrence of xeroderma pigmentosum in an uncle and nephew. Arch Dermatol 2009, 145(11): 1285 - 1291.

89. Poblete-Gutierrez P, Burgdorf WH, Has C, Berneburg M, Frank J: [Hereditary photodermatoses]. Hautarzt 2006, 57(12): 1067 - 1082.

90. Maeda T, Sato K, Minami H, Taguchi H, Yoshikawa K: PCR-RFLP analysis as an aid to genetic counseling of families of Japanese patients with group A xeroderma pigmentosum. J Invest Dermatol 1997, 109(3): 306 - 309.

91. Yang Y, Ding B, Wang K, Bu D, Tu P, Zhu X: DNA-based prenatal diagnosis in a Chinese family with xeroderma pigmentosum group A. Br J Dermatol 2004, 150(6): 1190 - 1193.

92. Itin PH, Fistarol SK: [Genetic counseling and DNA testing in patients with increased risks for malignant melanoma]. Ther Umsch 2003, 60(8): 469 - 472.

93. Oda T, Sue M, Sasaki Y, Ogura I: Diffusion-weighted magnetic resonance imaging in oral and maxillofacial lesions: preliminary study on diagnostic ability of apparent diffusion coefficient maps. Oral Radiol 2018, 34(3): 224 - 228.

94. Mendenhall WM, Ferlito A, Takes RP, Bradford CR, Corry J, Fagan JJ, Rinaldo A, Strojan P, Rodrigo JP: Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol 2012, 48(10): 918 - 922.

95. Balamucki CJ, DeJesus R, Galloway TJ, Mancuso AA, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM: Impact of radiographic findings on for prognosis skin cancer with perineural invasion. Am J Clin Oncol 2015, 38(3): 248 - 251.

96. Newlands C, Currie R, Memon A, Whitaker S, Woolford T: Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016, 130(S2): S125 - S132.

97. Marrazzo G, Thorpe R, Condie D, Pinho MC, Srivastava D: Clinical and Pathologic Factors Predictive of Positive Radiologic Findings in High-Risk Cutaneous Squamous Cell Carcinoma. Dermatol Surg 2015, 41(12): 1405 - 1410.

98. Ruiz ES, Karia PS, Morgan FC, Schmults CD: The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol 2017, 76(2): 217 - 225.

99. Gandhi MR, Panizza B, Kennedy D: Detecting and defining the anatomic extent of large nerve perineural spread of malignancy: comparing "targeted" MRI with the histologic findings following surgery. Head Neck 2011, 33(4): 469 - 475.

100. Williams LS, Mancuso AA, Mendenhall WM: Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys 2001, 49(4): 1061 - 1069.

101. Nemzek WR, Hecht S, Gandour-Edwards R, Donald P, McKennan K: Perineural spread of head and neck tumors: how accurate is MR imaging? AJNR Am J Neuroradiol 1998, 19(4): 701 - 706.

102. Buchwald HJ, Muller A, Kampmeier J, Lang GK: [Optical coherence tomography versus ultrasound biomicroscopy of conjunctival and eyelid lesions]. Klin Monbl Augenheilkd 2003, 220(12): 822 - 829.

103. Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S et al: MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 2018, 19(7): 916 - 929.

104. Bichakjian C, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bordeaux J, Bowen GM, Chen PL, Contreras CM, Mackenzie D et al: Basal cell skin cancer. NCCN clinical practice guidelines in oncology. Version 1.2019 - August 31.2018. 2019: 46.

105. Brodland DG, Zitelli JA: Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992, 27(2 Pt 1): 241 - 248.

106. Baker NJ, Webb AA, Macpherson D: Surgical management of cutaneous squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 2001, 39(2): 87 - 90.

107. Griffiths RW, Feeley K, Suvarna SK: Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery. Br J Plast Surg 2002, 55(4): 287 - 292.

108. Ang P, Tan AW, Goh CL: Comparison of completely versus incompletely excised cutaneous squamous cell carcinomas. Ann Acad Med Singapore 2004, 33(1): 68 - 70.

109. Nemet AY, Deckel Y, Martin PA, Kourt G, Chilov M, Sharma V, Benger R: Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol 2006, 142(2): 293 - 297.

110. Mourouzis C, Boynton A, Grant J, Umar T, Wilson A, Macpheson D, Pratt C: Cutaneous head and neck SCCs and risk of nodal metastasis - UK experience. J Craniomaxillofac Surg 2009, 37(8): 443 - 447.

111. Seretis K, Thomaidis V, Karpouzis A, Tamiolakis D, Tsamis I: Epidemiology of surgical treatment of nonmelanoma skin cancer of the head and neck in Greece. Dermatol Surg 2010, 36(1): 15 - 22.

112. van der Eerden PA, Prins ME, Lohuis PJ, Balm FA, Vuyk HD: Eighteen years of experience in Mohs micrographic surgery and conventional excision for nonmelanoma skin cancer treated by a single facial plastic surgeon and pathologist. Laryngoscope 2010, 120(12): 2378 - 2384.

113. Maciburko SJ, Townley WA, Hollowood K, Giele HP: Skin cancers of the hand: a series of 541 malignancies. Plast Reconstr Surg 2012, 129(6): 1329 - 1336.

114. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ: Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013, 133(5): 1188 - 1196.

115. Schell AE, Russell MA, Park SS: Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg 2013, 15(5): 337 - 343.

116. Jenkins G, Smith AB, Kanatas AN, Houghton DR, Telfer MR: Anatomical restrictions in the surgical excision of scalp squamous cell carcinomas: does this affect local recurrence and regional nodal metastases? Int J Oral Maxillofac Surg 2014, 43(2): 142 - 146.

117. Brinkman JN, Hajder E, van der Holt B, Den Bakker MA, Hovius SE, Mureau MA: The Effect of Differentiation Grade of Cutaneous Squamous Cell Carcinoma on Excision Margins, Local Recurrence, Metastasis, and Patient Survival: A Retrospective Follow-Up Study. Ann Plast Surg 2015, 75(3): 323 - 326.

118. Pugliano-Mauro M, Goldman G: Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 2010, 36(10): 1544 - 1553.

119. Batra RS, Kelley LC: Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol 2002, 138(8): 1043 - 1051.

120. Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R: Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005, 53(2): 253 - 260.

121. Bogdanov-Berezovsky A, Cohen AD, Glesinger R, Cagnano E, Rosenberg L: Risk factors for incomplete excision of squamous cell carcinomas. J Dermatolog Treat 2005, 16(5 - 6): 341 - 344.

122. Khan AA, Potter M, Cubitt JJ, Khoda BJ, Smith J, Wright EH, Scerri G, Crick A, Cassell OC, Budny PG: Guidelines for the excision of cutaneous squamous cell cancers in the United Kingdom: the best cut is the deepest. J Plast Reconstr Aesthet Surg 2013, 66(4): 467 - 471.

123. Fraunfelder FT, Zacarian SA, Limmer BL, Wingfield D: Cryosurgery for malignancies of the eyelid. Ophthalmology 1980, 87(6): 461 - 465.

124. Zacarian SA: Cryosurgery of cutaneous carcinomas. An 18-year study of 3,022 patients with 4,228 carcinomas. J Am Acad Dermatol 1983, 9(6): 947 - 956.

125. Holt PJ: Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988, 119(2): 231 - 240.

126. Kuflik EG, Gage AA: The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991, 24(6 Pt 1): 1002 - 1004.

127. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM: Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen"s disease. Br J Dermatol 1996, 135(5): 766 - 771.

128. Ahmed I, Berth-Jones J, Charles-Holmes S, O"Callaghan CJ, Ilchyshyn A: Comparison of cryotherapy with curettage in the treatment of Bowen"s disease: a prospective study. Br J Dermatol 2000, 143(4): 759 - 766.

129. Morton CA, Whitehurst C, Moore JV, MacKie RM: Comparison of red and green light in the treatment of Bowen"s disease by photodynamic therapy. Br J Dermatol 2000, 143(4): 767 - 772.

130. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM: Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001, 137(3): 319 - 324.

131. Salim A, Leman JA, McColl JH, Chapman R, Morton CA: Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen"s disease. Br J Dermatol 2003, 148(3): 539 - 543.

132. Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, Ibbotson S, Khemis A, Wolf P: Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol 2006, 142(6): 729 - 735.

133. Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, Motley RJ: Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen"s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006, 54(6): 1025 - 1032.

134. Peris K, Micantonio T, Fargnoli MC, Lozzi GP, Chimenti S: Imiquimod 5% cream in the treatment of Bowen"s disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006, 55(2): 324 - 327.

135. Hansen JP, Drake AL, Walling HW: Bowen"s Disease: a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg 2008, 34(7): 878 - 883.

136. Warshauer E, Warshauer BL: Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. J Drugs Dermatol 2008, 7(5): 447 - 451.

137. Lindemalm-Lundstam B, Dalenback J: Prospective follow-up after curettage-cryosurgery for scalp and face skin cancers. Br J Dermatol 2009, 161(3): 568 - 576.

138. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009, 145(12): 1431 - 1438.

139. Peikert JM: Prospective trial of curettage and cryosurgery in the management of non-facial, superficial, and minimally invasive basal and squamous cell carcinoma. Int J Dermatol 2011, 50(9): 1135 - 1138.

140. Overmark M, Koskenmies S, Pitkanen S: A Retrospective Study of Treatment of Squamous Cell Carcinoma In situ. Acta Derm Venereol 2016, 96(1): 64 - 67.

141. Varma S, Wilson H, Kurwa HA, Gambles B, Charman C, Pearse AD, Taylor D, Anstey AV: Bowen"s disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001, 144(3): 567 - 574.

142. Lui H, Hobbs L, Tope WD, Lee PK, Elmets C, Provost N, Chan A, Neyndorff H, Su XY, Jain H et al: Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 2004, 140(1): 26 - 32.

143. Haddad R, Nesher E, Weiss J, Skornick Y, Kashtan H: Photodynamic therapy for Bowen"s disease and squamous cell carcinoma of the skin. Photodiagnosis Photodyn Ther 2004, 1(3): 225 - 230.

144. Calzavara-Pinton PG, Venturini M, Sala R, Capezzera R, Parrinello G, Specchia C, Zane C: Methylaminolaevulinate-based photodynamic therapy of Bowen"s disease and squamous cell carcinoma. Br J Dermatol 2008, 159(1): 137 - 144.

145. Ko DY, Kim KH, Song KH: A randomized trial comparing methyl aminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up. Br J Dermatol 2014, 170(1): 165 - 172.

146. Bath-Hextall FJ, Matin RN, Wilkinson D, Leonardi-Bee J: Interventions for cutaneous Bowen"s disease. The Cochrane database of systematic reviews 2013(6): CD007281.

147. Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J: Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013, 347: f6153.

148. Honeycutt WM, Jansen GT: Treatment of squamous cell carcinoma of the skin. Arch Dermatol 1973, 108(5): 670 - 672.

149. Shiffman NJ: Squamous cell carcinomas of the skin of the pinna. Can J Surg 1975, 18(3): 279 - 283.

150. Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP: Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope 2009, 119(10): 1994 - 1999.

151. Hernandez-Machin B, Borrego L, Gil-Garcia M, Hernandez BH: Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol 2007, 46(5): 453 - 459.

152. Veness MJ, Delishaj D, Barnes EA, Bezugly A, Rembielak A: Current Role of Radiotherapy in Non-melanoma Skin Cancer. Clin Oncol (R Coll Radiol) 2019, 31(11): 749 - 758.

153. Grossi Marconi D, da Costa Resende B, Rauber E, de Cassia Soares P, Fernandes JMJ, Mehta N, Lopes Carvalho A, Kupelian PA, Chen A: Head and Neck Non-Melanoma Skin Cancer Treated By Superficial X-Ray Therapy: An Analysis of 1021 Cases. PLoS One 2016, 11(7): e0156544.

154. Tsao MN, Tsang RW, Liu FF, Panzarella T, Rotstein L: Radiotherapy management for squamous cell carcinoma of the nasal skin: the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 2002, 52(4): 973 - 979.

155. Abbatucci JS, Boulier N, Laforge T, Lozier JC: Radiation therapy of skin carcinomas: results of a hypofractionated irradiation schedule in 675 cases followed more than 2 years. Radiother Oncol 1989, 14(2): 113 - 119.

156. van Hezewijk M, Creutzberg CL, Putter H, Chin A, Schneider I, Hoogeveen M, Willemze R, Marijnen CA: Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiother Oncol 2010, 95(2): 245 - 249.

157. Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH: Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed 2003, 19(3): 134 - 141.

158. Церковский ДА, Мазуренко АН, Петровская НА, Артемьева ТП: Фотодинамическая терапия базальноклеточного рака кожи с фотосенсибилизатором фотолон. Biomedical Photonics 2017, 6(1): 12 - 19.

159. Chan AL, Juarez M, Allen R, Volz W, Albertson T: Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces. Photodermatol Photoimmunol Photomed 2005, 21(2): 72 - 78.

160. Kochneva EV, Filonenko EV, Vakulovskaya EG, Scherbakova EG, Seliverstov OV, Markichev NA, Reshetnickov AV: Photosensitizer Radachlorin(R): Skin cancer PDT phase II clinical trials. Photodiagnosis Photodyn Ther 2010, 7(4): 258 - 267.

161. Rosen T, Harting M, Gibson M: Treatment of Bowen"s disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg 2007, 33(4): 427 - 431; discussion 431 - 422.

162. Ross AS, Schmults CD: Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg 2006, 32(11): 1309 - 1321.

163. Renzi C, Caggiati A, Mannooranparampil TJ, Passarelli F, Tartaglione G, Pennasilico GM, Cecconi S, Potenza C, Pasquini P: Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol 2007, 33(3): 364 - 369.

164. Ahmed MM, Moore BA, Schmalbach CE: Utility of head and neck cutaneous squamous cell carcinoma sentinel node biopsy: a systematic review. Otolaryngol Head Neck Surg 2014, 150(2): 180 - 187.

165. Fukushima S, Masuguchi S, Igata T, Harada M, Aoi J, Miyashita A, Nakahara S, Inoue Y, Jinnin M, Shiraishi S et al: Evaluation of sentinel node biopsy for cutaneous squamous cell carcinoma. J Dermatol 2014, 41(6): 539 - 541.

166. Schmitt AR, Brewer JD, Bordeaux JS, Baum CL: Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 2014, 150(1): 19 - 24.

167. Takahashi A, Imafuku S, Nakayama J, Nakaura J, Ito K, Shibayama Y: Sentinel node biopsy for high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol 2014, 40(10): 1256 - 1262.

168. Allen JE, Stolle LB: Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol 2015, 41(2): 197 - 200.

169. Krediet JT, Beyer M, Lenz K, Ulrich C, Lange-Asschenfeldt B, Stockfleth E, Terhorst D: Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. Br J Dermatol 2015, 172(4): 1029 - 1036.

170. Durham AB, Lowe L, Malloy KM, McHugh JB, Bradford CR, Chubb H, Johnson TM, McLean SA: Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma on the Head and Neck. JAMA Otolaryngol Head Neck Surg 2016, 142(12): 1171 - 1176.

171. Gore SM, Shaw D, Martin RC, Kelder W, Roth K, Uren R, Gao K, Davies S, Ashford BG, Ngo Q et al: Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 2016, 38 Suppl 1: E884 - 889.

172. Maruyama H, Tanaka R, Fujisawa Y, Nakamura Y, Ito S, Fujimoto M: Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma. J Dermatol 2017, 44(4): 431 - 437.

173. Hauschild A, Breuninger H, Kaufmann R, Kortmann RD, Klein M, Werner J, Reifenberger J, Dirschka T, Garbe C: Brief S2k guidelines - Basal cell carcinoma of the skin. J Dtsch Dermatol Ges 2013, 11 Suppl 3: 10 - 15, 11 - 16.

174. Rowe DE, Carroll RJ, Day CL, Jr.: Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989, 15(4): 424 - 431.

175. Rowe DE, Carroll RJ, Day CL, Jr.: Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989, 15(3): 315 - 328.

176. Petit JY, Avril MF, Margulis A, Chassagne D, Gerbaulet A, Duvillard P, Auperin A, Rietjens M: Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 2000, 105(7): 2544 - 2551.

177. Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, Guillaume JC, Chalon R, Petit JY, Sancho-Garnier H et al: Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997, 76(1): 100 - 106.

178. Dundar Y, Cannon RB, Hunt JP, Monroe M, Suneja G, Hitchcock YJ: Radiotherapy regimens in patients with nonmelanoma head and neck skin cancers. Int J Dermatol 2018, 57(4): 441 - 448.

179. Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD: Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009, 35(4): 574 - 585.

180. Veness MJ, Morgan GJ, Palme CE, Gebski V: Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005, 115(5): 870 - 875.

181. Wray J, Amdur RJ, Morris CG, Werning J, Mendenhall WM: Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp. Radiat Oncol 2015, 10: 199.

182. Тимофеев ЛВ, Саакян СВ, Волошин СВ, Архипов АЮ: Аппликаторы для офтальмоонкологии. Стронций-90 + Иттрий-90. Москва; 2019.

183. Chopdar A: Carbon-dioxide laser treatment of eye lid lesions. Trans Ophthalmol Soc U K 1985, 104 (Pt 2): 176 - 180.

184. Вальский ВВ: Крупнофракционная брахитерапия злокачественных опухолей конъюнктивы. In: Достижения и перспективы офтальмоонкологии. edn. Москва; 2001: 98 - 100.

185. Бровкина АФ: Лучевая терапия в лечении опухолей органа зрения. Клин офтальмология 2003, 4(1): 15 - 19.

186. Тимофеев ЛВ: Физические, технические, некоторые радиобиологические и медицинские аспекты контактной лучевой (бета-) терапии. Москва; 2016.

187. Тимофеев ЛВ: Расчетные методы дозиметрии бета-излучения. Москва: Типография "Ваш формат"; 2017.

188. Laskar S, Gurram L, Laskar SG, Chaudhari S, Khanna N, Upreti R: Superficial ocular malignancies treated with strontium-90 brachytherapy: long term outcomes. J Contemp Brachytherapy 2015, 7(5): 369 - 373.

189. Lecuona K, Stannard C, Hart G, Rice J, Cook C, Wetter J, Duffield M: The treatment of carcinoma in situ and squamous cell carcinoma of the conjunctiva with fractionated strontium-90 radiation in a population with a high prevalence of HIV. Br J Ophthalmol 2015, 99(9): 1158 - 1161.

190. Stannard C, Sauerwein W, Maree G, Lecuona K: Radiotherapy for ocular tumours. Eye (Lond) 2013, 27(2): 119 - 127.

191. Veness MJ, Palme CE, Smith M, Cakir B, Morgan GJ, Kalnins I: Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope 2003, 113(10): 1827 - 1833.

192. Hinerman RW, Indelicato DJ, Amdur RJ, Morris CG, Werning JW, Vaysberg M, Kirwan J, Mendenhall WM: Cutaneous squamous cell carcinoma metastatic to parotid-area lymph nodes. Laryngoscope 2008, 118(11): 1989 - 1996.

193. Jol JA, van Velthuysen ML, Hilgers FJ, Keus RB, Neering H, Balm AJ: Treatment results of regional metastasis from cutaneous head and neck squamous cell carcinoma. Eur J Surg Oncol 2003, 29(1): 81 - 86.

194. Audet N, Palme CE, Gullane PJ, Gilbert RW, Brown DH, Irish J, Neligan P: Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck 2004, 26(8): 727 - 732.

195. Khurana VG, Mentis DH, O"Brien CJ, Hurst TL, Stevens GN, Packham NA: Parotid and neck metastases from cutaneous squamous cell carcinoma of the head and neck. Am J Surg 1995, 170(5): 446 - 450.

196. O"Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS, Jackson MA: Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002, 24(5): 417 - 422.

197. Chua MS, Veness MJ, Morgan G, Shakespeare T, Hehir A, Gebski V, Cakir B, Tiver KW: Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. Australas Radiol 2002, 46(2): 174 - 179.

198. Dona E, Veness MJ, Cakir B, Morgan GJ: Metastatic cutaneous squamous cell carcinoma to the parotid: the role of surgery and adjuvant radiotherapy to achieve best outcome. ANZ J Surg 2003, 73(9): 692 - 696.

199. Palme CE, O"Brien CJ, Veness MJ, McNeil EB, Bron LP, Morgan GJ: Extent of parotid disease influences outcome in patients with metastatic cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003, 129(7): 750 - 753.

200. Apisarnthanarax S, Dhruva N, Ardeshirpour F, Tepper JE, Shores CG, Rosenman JG, Shockley WW, Hayward MC, Hayes DN: Concomitant radiotherapy and chemotherapy for high-risk nonmelanoma skin carcinomas of the head and neck. Int J Surg Oncol 2011, 2011: 464829.

201. Kwan W, Wilson D, Moravan V: Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004, 60(2): 406 - 411.

202. Balamucki CJ, Mancuso AA, Amdur RJ, Kirwan JM, Morris CG, Flowers FP, Stoer CB, Cognetta AB, Mendenhall WM: Skin carcinoma of the head and neck with perineural invasion. Am J Otolaryngol 2012, 33(4): 447 - 454.

203. Maubec E, Helfen S, Scheer-Senyarich I, Boubaya M, Schischmanoff O, Alloux C, Deschamps L, Petrow P, Lopez I, Tibi A et al: CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC). Journal of Clinical Oncology 2017, 35(15_suppl): TPS9596 - TPS9596.

204. Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, Pavlick AC, Carucci JA: Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. JAMA Dermatol 2017, 153(4): 299 - 303.

205. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016, 17(7): 956 - 965.

206. Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid-Zalaudek K, Zalaudek I: Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature. Eur J Cancer 2017, 83: 99 - 102.

207. Papadopoulos KP, Johnson ML, Lockhart AC, Moore KN, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ et al: First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res 2019.

208. Choi FD, Kraus CN, Elsensohn AN, Carley SK, Lehmer LM, Nguyen RT, Linden KG, Shiu J: Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. J Am Acad Dermatol 2019.

209. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C et al: Nivolumab vs investigator"s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018, 81: 45 - 51.

210. Markham A, Duggan S: Cemiplimab: First Global Approval. Drugs 2018, 78(17): 1841 - 1846.

211. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS et al: PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 2018, 379(4): 341 - 351.

212. Sidaway P: Cemiplimab effective in cutaneous SCC. Nat Rev Clin Oncol 2018, 15(8): 472.

213. Ahmed SR, Petersen E, Patel R, Migden MR: Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol 2019, 12(10): 947 - 951.

214. Ali SA, Arman HE, Patel AA, Birhiray RE: Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation. J Oncol Pract 2019: JOP1900567.

215. Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A et al: Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther 2019, 18(11): 2051 - 2062.

216. Hernandez-Guerrero T, Doger B, Moreno V: Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Drugs Today (Barc) 2019, 55(8): 485 - 494.

217. Vanhakendover L, Lebas E, Libon F, Wauters O, Dezfoulian B, Marchal N, Rorive A, Piret P, Quatresooz P, Jacquemin D et al: [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab]. Rev Med Liege 2019, 74(7 - 8): 436 - 440.

218. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C et al: Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016, 375(19): 1856 - 1867.

219. Modification of the Dosage Regimen for Nivolumab [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm]

220. Guthrie TH, Porubsky ES: Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope 1982, 92(11): 1298 - 1299.

221. Guthrie TH, Jr., McElveen LJ, Porubsky ES, Harmon JD: Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 1985, 55(8): 1629 - 1632.

222. Ikegawa S, Saida T, Obayashi H, Sasaki A, Esumi H, Ikeda S, Kiyohara Y, Hayasaka K, Ishihara K: Cisplatin combination chemotherapy in squamous cell carcinoma and adenoid cystic carcinoma of the skin. J Dermatol 1989, 16(3): 227 - 230.

223. Khansur T, Kennedy A: Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 1991, 67(8): 2030 - 2032.

224. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA: Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000, 88(4): 876 - 883.

225. Goppner D, Nekwasil S, Franke I, Gollnick H, Leverkus M: Successful combination therapy of a locally advanced squamous cell carcinoma of the skin with cetuximab and gamma-irradiation. J Dtsch Dermatol Ges 2010, 8(10): 826 - 828.

226. DeConti RC: Chemotherapy of squamous cell carcinoma of the skin. Semin Oncol 2012, 39(2): 145 - 149.

227. Bejar C, Maubec E: Therapy of advanced squamous cell carcinoma of the skin. Curr Treat Options Oncol 2014, 15(2): 302 - 320.

228. Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quereux G, Dreno B: Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat 2014, 25(5): 424 - 427.

229. Conen KL, Fischer N, Hofbauer GF, Shafaeddin-Schreve B, Winterhalder R, Rochlitz C, Zippelius A: Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series. Dermatology 2014, 229(2): 97 - 101.

230. Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, Zarate D, Simpson F, Porceddu SV: Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 2014, 25(10): 2047 - 2052.

231. Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG: Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 2015, 37(6): 840 - 845.

232. Nottage MK, Lin C, Hughes BG, Kenny L, Smith DD, Houston K, Francesconi A: Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 2017, 39(4): 679 - 683.

233. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 2010, 11(1): 21 - 28.

234. Goldberg H, Tsalik M, Bernstein Z, Haim N: [Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas]. Harefuah 1994, 127(7 - 8): 217 - 221, 286.

235. Petre A, Dalban C, Karabajakian A, Neidhardt EM, Roux PE, Poupart M, Deneuve S, Zrounba P, Fayette J: Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. Oncotarget 2018, 9(31): 22038 - 22046.

236. Muzaffar J, Khushalani NI, Russell JS, Parameswaran J, Kirtane K, Iglesia JDL, Slebos R, Chung CH: A phase II study of capecitabine (Cape) or 5-fluorouracil (5-FU) with pegylated interferon alpha-2b (Peg-IFNA-2b) in unresectable/metastatic cutaneous squamous cell carcinoma (CSCC). Journal of Clinical Oncology 2019, 37(15_suppl): e21020 - e21020.

237. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V et al: Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011, 29(25): 3419 - 3426.

238. Gurney H: How to calculate the dose of chemotherapy. Br J Cancer 2002, 86(8): 1297 - 1302.

239. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001, 19(17): 3733 - 3739.

240. Silver JK, Baima J: Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013, 92(8): 715 - 727.

241. Nilsson H, Angeras U, Bock D, Borjesson M, Onerup A, Fagevik Olsen M, Gellerstedt M, Haglind E, Angenete E: Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016, 6(1): e007997.

242. Siegel GW, Biermann JS, Chugh R, Jacobson JA, Lucas D, Feng M, Chang AC, Smith SR, Wong SL, Hasen J: The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Healthc 2015, 8: 109 - 115.

243. Shehadeh A, El Dahleh M, Salem A, Sarhan Y, Sultan I, Henshaw RM, Aboulafia AJ: Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients" outcome. Hematol Oncol Stem Cell Ther 2013, 6(3 - 4): 105 - 111.

244. Cox CL, Montgomery M, Oeffinger KC, Leisenring W, Zeltzer L, Whitton JA, Mertens AC, Hudson MM, Robison LL: Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009, 115(3): 642 - 654.

245. Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, Committee EG: Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018, 29 (Suppl 4): iv166 - iv191.

246. Oren R, Zagury Al, Katzir O, Kollender Y, Meller I: Musculoskeletal Cancer Surgery. In., edn. Edited by Malawer. Dordrecht: Springer; 2013: 583 - 593.

247. Committee. NMA: Topic: The Diagnosis and Treatment of Lymphedema. Position Statement of the National Lymphedema Network. In.; 2011: 1 - 19.

248. Segal R, Zwaal C, Green E, Tomasone JR, Loblaw A, Petrella T, Exercise for People with Cancer Guideline Development G: Exercise for people with cancer: a systematic review. Curr Oncol 2017, 24(4): e290 - e315.

249. Boyd C, Crawford C, Paat CF, Price A, Xenakis L, Zhang W, Evidence for Massage Therapy Working G: The Impact of Massage Therapy on Function in Pain Populations - A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations. Pain Med 2016, 17(8): 1553 - 1568.

250. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J: A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005 - 2017). PM R 2017, 9(9S2): S347 - S384.

251. Hu M, Lin W: Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol 2012, 127(3): 156 - 164.

252. Bland KA, Zadravec K, Landry T, Weller S, Meyers L, Campbell KL: Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol 2019, 136: 79 - 85.

253. Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014, 44(9): 1289 - 1304.

254. Lee JM, Look RM, Turner C, Gardiner SK, Wagie T, Douglas J, Sorenson L, Evans L, Kirchner S, Dashkoff C et al: Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 2012, 30(15_suppl): 9019 - 9019.

255. Rick O, von Hehn U, Mikus E, Dertinger H, Geiger G: Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2017, 38(2): 85 - 94.

256. Kilinc M, Livanelioglu A, Yildirim SA, Tan E: Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014, 46(5): 454 - 460.

257. Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L: Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014, 9(9): e107418.

258. Westphal JG, Schulze PC: Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018, 10 (Suppl 35): S4391 - S4399.

259. Ross M, Fischer-Cartlidge E: Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs 2017, 21(2): 226 - 233.

260. Kessels E, Husson O, van der Feltz-Cornelis CM: The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018, 14: 479 - 494.

261. Rief H, Omlor G, Akbar M, Welzel T, Bruckner T, Rieken S, Haefner MF, Schlampp I, Gioules A, Habermehl D et al: Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 2014, 14: 67.

262. Bensadoun RJ, Nair RG: Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy. Photomed Laser Surg 2015, 33(10): 487 - 491.

263. Temoshok L: Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response. Soc Sci Med 1985, 20(8): 833 - 840.

264. Dirksen SR: Perceived well-being in malignant melanoma survivors. Oncol Nurs Forum 1989, 16(3): 353 - 358.

265. Lichtenthal WG, Cruess DG, Schuchter LM, Ming ME: Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma. J Health Psychol 2003, 8(6): 705 - 719.

266. Sollner W, Zschocke I, Zingg-Schir M, Stein B, Rumpold G, Fritsch P, Augustin M: Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics 1999, 40(3): 239 - 250.

267. Devine D, Parker PA, Fouladi RT, Cohen L: The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003, 12(5): 453 - 462.

268. Folkman S, Lazarus RS, Gruen RJ, DeLongis A: Appraisal, coping, health status, and psychological symptoms. J Pers Soc Psychol 1986, 50(3): 571 - 579.

269. Беляев АМ, Чулкова ВА, Семиглазова ТЮ, Рогачев МВ (eds.): Онкопсихология для врачей-онкологов и медицинских психологов. Руководство. СПб: Любавич; 2017.

270. Fawzy FI, Cousins N, Fawzy NW, Kemeny ME, Elashoff R, Morton D: A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry 1990, 47(8): 720 - 725.

271. Holland JC, Passik S, Kash KM, Russak SM, Gronert MK, Sison A, Lederberg M, Fox B, Baider L: The role of religious and spiritual beliefs in coping with malignant melanoma. Psychooncology 1999, 8(1): 14 - 26.

272. Baider L, Perry S, Sison A, Holland J, Uziely B, DeNour AK: The role of psychological variables in a group of melanoma patients. An Israeli sample. Psychosomatics 1997, 38(1): 45 - 53.

273. Lehto US, Ojanen M, Kellokumpu-Lehtinen P: Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 2005, 16(5): 805 - 816.

274. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL: Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993, 50(9): 681 - 689.

275. Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, Fahey JL: A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry 1990, 47(8): 729 - 735.

276. Fawzy FI, Canada AL, Fawzy NW: Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry 2003, 60(1): 100 - 103.

277. Boesen EH, Boesen SH, Frederiksen K, Ross L, Dahlstrom K, Schmidt G, Naested J, Krag C, Johansen C: Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2007, 25(36): 5698 - 5703.

278. Boesen EH, Ross L, Frederiksen K, Thomsen BL, Dahlstrom K, Schmidt G, Naested J, Krag C, Johansen C: Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2005, 23(6): 1270 - 1277.

279. McLoone J, Menzies S, Meiser B, Mann GJ, Kasparian NA: Psycho educational interventions for melanoma survivors: a systematic review. Psychooncology 2013, 22(7): 1444 - 1456.

280. Sample A, He YY: Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 2018, 34(1): 13 - 24.

281. Craig S, Earnshaw CH, Viros A: Ultraviolet light and melanoma. J Pathol 2018, 244(5): 578 - 585.

282. Runger TM: Mechanisms of Melanoma Promotion by Ultraviolet Radiation. J Invest Dermatol 2016, 136(9): 1751 - 1752.

283. Green AC, Williams GM, Logan V, Strutton GM: Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011, 29(3): 257 - 263.

284. Ghiasvand R, Weiderpass E, Green AC, Lund E, Veierod MB: Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. J Clin Oncol 2016, 34(33): 3976 - 3983.

285. Marcil I, Stern RS: Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000, 136(12): 1524 - 1530.

286. Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, Stricker BH, Nijsten T: Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010, 146(8): 848 - 855.

287. Sanchez G, Nova J, Rodriguez-Hernandez AE, Medina RD, Solorzano-Restrepo C, Gonzalez J, Olmos M, Godfrey K, Arevalo-Rodriguez I: Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database Syst Rev 2016, 7: CD011161.

288. Badertscher N, Meier M, Rosemann T, Braun R, Cozzio A, Tag B, Wensing M, Tandjung R: The role of skin self-examination at the Swiss skin cancer day. BMC Health Serv Res 2014, 14: 581.

289. Wu S, Han J, Li WQ, Li T, Qureshi AA: Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. Am J Epidemiol 2013, 178(6): 890 - 897.

290. Karagas MR, Stukel TA, Greenberg ER, Baron JA, Mott LA, Stern RS: Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992, 267(24): 3305 - 3310.

291. Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC: Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. J Am Acad Dermatol 2009, 61(2): 247 - 251.

292. Flohil SC, Koljenovic S, de Haas ER, Overbeek LI, de Vries E, Nijsten T: Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. Br J Dermatol 2011, 165(4): 874 - 881.

293. Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T: Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 2013, 49(10): 2365 - 2375.

294. Aryasit O, Preechawai P, Hajeewaming N: Clinicopathologic Characteristics and Predictors Affecting Survival Outcome of Eyelid Malignancy. J Craniofac Surg 2019, 30(5): 1516 - 1519.

295. Schneider J: The teaspoon rule of applying sunscreen. Arch Dermatol 2002, 138(6): 838 - 839.

296. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6): 649 - 655.